Estimate how long vaccine immunity lasts: model antibody decay, T-cell memory, and booster timing based on vaccine type, age, and immunological factors.
Vaccine-induced immunity does not last forever — antibody levels naturally decline over time, and the rate of decline depends on the vaccine type, number of doses, age, and individual immune factors. The Vaccine Immunity Duration Calculator models this antibody decay over time and estimates when protection drops below key thresholds.
Using published immunological data on antibody half-lives for different vaccine platforms (mRNA, viral vector, inactivated, protein subunit, and live attenuated), this calculator projects your estimated antibody level at any point after vaccination. It considers critical factors like age-related immune decline, immunosuppression, and hybrid immunity from prior infection.
Importantly, the calculator distinguishes between antibody-mediated protection (which wanes faster) and T-cell memory (which persists much longer and sustains protection against severe disease). This dual-layer model explains why vaccines continue to prevent hospitalizations and deaths long after their ability to prevent mild infection has declined. Check the example with realistic values before reporting.
Understanding how your vaccine immunity changes over time helps you make informed decisions about boosters, risk behavior, and protective measures. Rather than guessing whether your protection has "worn off," you can estimate where you are on the immunity curve.
This is particularly valuable for immunocompromised individuals, elderly people, and healthcare workers who need to optimize their protection timing.
Antibody Level = Peak Level × (0.5)^(days / half-life) Peak Level adjusted for: dose count, hybrid immunity, immunosuppression, age Protection = Mapped from antibody level thresholds Severe Protection = 0.5 × Infection Protection + 0.5 × T-Cell Memory Factor T-Cell Memory = (0.5)^(days / cell memory half-life)
Result: ~25% antibody level, ~60% infection protection, ~72% severe disease protection
mRNA antibody half-life ~90 days. After 180 days (2 half-lives), antibodies drop to ~25% of peak. T-cell memory remains strong at ~90% of peak, sustaining severe disease protection.
Vaccine immunity operates through two complementary mechanisms: humoral immunity (antibodies) and cellular immunity (T cells). Antibodies are proteins that circulate in the blood and can neutralize pathogens before they infect cells. They are the first line of defense and primarily prevent infection. T cells, particularly cytotoxic CD8+ T cells, destroy infected cells and are critical for preventing severe disease and death.
After vaccination, antibody levels peak at 2-4 weeks, then begin a biphasic decline: a rapid initial phase as short-lived plasma cells die, followed by a slower decline maintained by long-lived memory B cells and plasma cells in the bone marrow. T-cell memory, in contrast, is established within weeks and can persist for years to decades.
The observation that vaccines continue to prevent hospitalizations long after they stop preventing mild infections is explained by the different thresholds required. Preventing infection requires high levels of circulating neutralizing antibodies at mucosal surfaces. Preventing severe disease requires enough immune memory (both antibody and cellular) to mount a rapid response after an infection has already begun. Since the severe disease threshold is lower, protection against severe outcomes persists much longer.
Immune responses to vaccination vary enormously between individuals. Factors include age, genetics, nutritional status, stress, sleep, concurrent medications (particularly immunosuppressants), and prior immune experience. Two people receiving the same vaccine on the same day may have 10-fold different antibody levels at one month. This calculator uses population-level averages and should be interpreted as a general guide, not an individual prediction.
After vaccination, plasma cells produce antibodies at high levels, but many of these cells are short-lived. Over weeks and months, antibody production shifts to long-lived memory B cells that maintain lower but more stable levels.
No. T-cell memory persists much longer than circulating antibodies and provides protection against severe disease. Even with low antibody levels, memory B and T cells can mount a rapid response upon exposure.
Hybrid immunity combines vaccine-induced and infection-induced immunity. Studies show this produces stronger and more durable protection than either alone, with higher peak antibody levels and broader immune memory.
Immune function (immunosenescence) declines with age. Older adults typically produce lower peak antibody levels and their antibodies decline faster, which is why booster doses are more important for elderly populations.
The optimal booster timing depends on your risk profile. Generally, when estimated antibody levels drop below 25% of peak and community transmission is occurring, a booster is recommended. Immunocompromised individuals may need boosters sooner.
Live attenuated vaccines (like MMR) typically provide the longest immunity, often lasting decades. Among newer platforms, protein subunit and mRNA vaccines with boosters show durable responses, though long-term data is still emerging.